Breaking News

Fujifilm Expands Fill Finish Services

To include late phase and commercial production of gene therapies and viral vaccines

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Fujifilm Diosynth Biotechnologies has extended its gene therapy and viral vaccine fill/finish capabilities to provide services in support of late phase candidates and commercial supply. Fujifilm has invested in Vanrx Pharmasystems’ SA25 Aseptic Filling Workcell gloveless isolator technology with automated environmental monitoring and no glass to glass contact. Fujifilm’s fill finish services offer rapid changeover between drug products and containers, production predictability and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters